Alnylam Pharmaceuticals (ALNY) was Reiterated by Chardan Capital Markets to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 89 from a previous price target of $73 . Chardan Capital Markets advised their investors in a research report released on Nov 30, 2016.
Many Wall Street Analysts have commented on Alnylam Pharmaceuticals. Shares were Reiterated by Needham on Nov 16, 2016 to “Buy” and Lowered the Price Target to $ 98 from a previous price target of $137 .Alnylam Pharmaceuticals was Resumed by Leerink Partners to “Mkt Perform” on Nov 10, 2016. Alnylam Pharmaceuticals was Downgraded by Morgan Stanley to ” Equal-Weight” on Oct 7, 2016.
On the company’s financial health, Alnylam Pharmaceuticals reported $-1.21 EPS for the quarter, missing the analyst consensus estimate by $ -0.05 based on the information available during the earnings call on Nov 2, 2016. Analyst had a consensus of $-1.16. The company had revenue of $13.65 million for the quarter, compared to analysts expectations of $9.90 million. The company’s revenue was up 116.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.91 EPS.
Alnylam Pharmaceuticals opened for trading at $45.53 and hit $47.06 on the upside on Tuesday, eventually ending the session at $46.03, with a gain of 1.59% or 0.72 points. The heightened volatility saw the trading volume jump to 10,29,078 shares. Company has a market cap of $3,950 M.
In a different news, on Oct 14, 2016, David E I Pyott (director) purchased 27,900 shares at $37.00 per share price. According to the SEC, on Apr 21, 2016, John Maraganore (Chief Executive Officer) sold 30,151 shares at $67.87 per share price. On Mar 10, 2016, Michael W Bonney (director) purchased 2,000 shares at $58.36 per share price, according to the Form-4 filing with the securities and exchange commission.
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics based on its ribonucleic acid interference (RNAi). The Companys pipeline focuses in three strategic therapeutic areas (STArs): Genetic Medicines with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease with a pipeline of RNAi therapeutics toward genetically validated liver-expressed disease in cardiovascular and metabolic diseases and hepatic infectious disease with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases. Its products include Patisiran (ALN-TTR02) Revusiran (ALN-TTRsc) ALN-AT3 ALN-CC5 ALN-AS1 ALN-AAT ALN-GO1 ALN-TMP ALN-PCS ALN-PCSsc ALN-AC3 ALN-ANG ANGPTL3 ALN-HBV ALN-HDV and ALN-PDL. The Company is developing two investigational RNAi therapeutic candidates for TTR-Mediated Amyloidosis (ATTR): patisiran and revusiran.